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Abstract 
Epidermal growth factor receptor (EGFR) stimulates proliferative and survival signals. 
Activating mutations of EGFR are involved in the aetiology and maintenance of the 
malignant phenotype of lung tumours. We previously described the frequent association of 
these mutations with the decreased expression of the p14ARF tumour suppressor, another 
common feature of lung cancer. Based on these data, we postulated that p14ARF could protect 
cells against untimely or excessive mitotic signals induced by mutant EGFR. In this study, we 
demonstrate that p14ARF promotes apoptosis in lung tumour cells harboring the EGFR L858R 
mutation through the accumulation of phosphorylated STAT3 on Tyr 705 residue, which 
leads to Bcl-2 downregulation. Using siRNA against PTP-RT, the phosphatase that 
specifically targets Tyr 705 residue, we show that accumulation of pSTAT3-Tyr705 promotes 
EGFR L858R mutant cell death, thereby confirming the existence of a STAT3-dependent pro-
apoptotic pathway in these cells. Finally, we show that expression of the EGFR L858R 
mutant represses p14ARF expression and inhibits STAT3/Bcl-2 signalling. These results 
identify a novel link between the p14ARF and EGFR pathways and suggest that EGFR L858R 
counteracts the pro-apoptotic function of p14ARF by downregulating its expression to promote 
carcinogenesis.  
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Introduction 
 Epidermal growth factor receptor (EGFR) is a membrane-bound receptor tyrosine 
kinase that belongs to the ErbB subfamily (Blume-Jensen and Hunter, 2001). Upon ligand 
binding, EGFR initiates activation of a series of cellular signal transduction pathways that 
regulate proliferation and survival (Jorissen et al., 2003; Olayioye et al., 2000; Yarden, 2001). 
In agreement with an oncogenic role of EGFR, increased levels of EGFR gene expression are 
observed in a variety of human cancers, including carcinoma of the lung, in which EGFR 
overexpression is correlated with a poor prognosis (Hirsch et al., 2003; Krause and Van Etten, 
2005; Nicholson et al., 2001; Ohsaki et al., 2000). Somatic-activating mutations in the 
tyrosine kinase domain of EGFR are also observed in lung adenocarcinomas and are 
associated with a high likelihood of clinical response to treatment with EGFR tyrosine kinase 
inhibitors (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). Most lung adenocarcinoma-
associated somatic mutations are represented by the in-frame deletion of amino acids 47-750 
in exon 19 (Del19) and the missense substitution L858R in exon 21 (L858R) (Shigematsu et 
al., 2005). These kinase domain mutations in EGFR are generally referred to as activating 
mutations, as they result in the increased activity of the receptor, leading to the 
hyperactivation of downstream pro-survival pathways (PI3K/AKT, STAT) and oncogenic 
transformation (RAS/MAPK) (Greulich et al., 2005; Jiang et al., 2005; Sordella et al., 2004). 
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is 
important in mediating the pro-survival effects of mutant EGFR (Jorissen et al., 2003). 
STAT3 becomes activated through the phosphorylation of tyrosine residue 705 by Janus 
kinases in response to cytokine signalling or by receptors with intrinsic tyrosine kinase 
activity, such as EGFR (Zhong et al., 1994). Phosphorylation results in dimerisation and 
translocation of STAT3 to the nucleus, where it activates transcription of a wide variety of 
genes involved in cell growth and survival (Bowman et al., 2000; Bromberg and Darnell, 
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2000; Levy and Darnell, 2002). STAT3 is transiently activated in normal cells but is 
constitutively activated in lung adenocarcinoma cells expressing activating mutant EGFR 
(Haura et al., 2005b; Mukohara et al., 2003). 
 The p14ARF protein (p14ARF in humans and p19ARF in mice) is encoded in the 
INK4a/ARF locus, together with p16INK4a (Sherr, 2001). p14ARF is a nuclear protein with 
tumour suppressor activity and is a key component of major signalling pathways that are 
responsible for restraining abnormal cell growth and for maintaining genomic stability in 
response to DNA damage and oncogenic stress (Ozenne et al.). p14ARF is a key activator of 
the p53 pathway (Sharpless NE Mutat Res 2005). p14ARF also displays inhibitory cell growth 
control independently of p53 (Ozenne et al.; Sherr, 2006). Therefore, p14ARF is a critical 
component of tumour surveillance and has a strong protective role against lung cancer 
development (Eymin et al., 2003). It has been shown that p14ARF expression is frequently 
downregulated in human lung cancer, especially in small cell lung cancer and lung 
adenocarcinoma (Gazzeri et al., 1998; Hsu et al., 2004; Vonlanthen et al., 1998). More 
recently, we observed that nearly all lung adenocarcinoma with EGFR L858R or Del 19 
activating mutations have low or undetectable levels of p14ARF protein (Mounawar et al., 
2007), suggesting that p14ARF could be part of a failsafe mechanism protecting cells against 
untimely or excessive mitotic signals induced by EGFR signalling. In agreement with such a 
role, we report here that p14ARF inhibits the proliferation of EGFR L858R mutant cells by 
inducing cell death. This process involves the activation of a STAT3-dependent pro-apoptotic 
signalling pathway aimed at restraining the expression of Bcl-2. Furthermore, we show that 
EGFR L858R inhibits p14ARF expression and in this way counteracts the pro-apoptotic 
p14ARF/STAT3 pathway. These results provide the first evidence of cross talk between the 
p14ARF and mutant EGFR pathways. 
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Results 
Expression of p14ARF promotes apoptosis in EGFR L858R mutant cells  
 To study the existence of a potential interplay between p14ARF and EGFR, we first 
performed a western blot analysis of p14ARF expression in a panel of lung cancer cell lines 
with different EGFR/Her2 status. As illustrated in Figure 1a, a strong variation of p14ARF 
expression levels was observed among the cell lines. However and in agreement with our 
previous findings in lung primary tumors (Mounawar et al., 2007), a low level of p14ARF was 
more frequently observed in cell lines with mutant EGFR. To investigate the relationships 
linking p14ARF and mutant EGFR, we choose two representative cell lines carrying the EGFR 
L858R mutation and expressing low level of p14ARF, the H1975 and H3255 cell lines. H1975 
cells were transfected with an expression vector encoding the human p14ARF protein and 
stained with trypan blue to evaluate cell number. Because H1975 cells are difficult to 
transfect, they were selected with geneticin (G418) in the culture medium for 6 days before 
staining. We observed a 60% decrease in cell number upon p14ARF transfection compared to 
cells transfected with a control empty vector (Figure 1b). Cell cycle profiling of p14ARF 
transfected cells failed to detect any significant changes in G1/S/G2 phase distribution (data 
not shown). In contrast, active caspase3 staining in p14ARF transfected cells clearly revealed 
apoptosis 72 hours post-transfection (Figure 1c). Although H1975 cells express a very low 
level of p14ARF, its depletion using specific siRNA promoted the proliferation of EGFR 
L858R mutant cells compared to control mismatch siRNA (Figure 1d). Similar results were 
obtained in H3255 cells (Supplementary Figure S1). These results indicate that p14ARF 
inhibits the proliferation of EGFR L858R mutant cells by inducing apoptosis.  
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p14ARF-mediated apoptosis involves the accumulation of pSTAT3-Y705 
PI3K/Akt, Jak/STAT and MEK/ERK are key signal transduction pathways activated by 
EGFR (Jorissen et al., 2003). Therefore, we studied the status of AKT, STAT3/5 and ERK 
proteins in response to p14ARF. H1975 cells were transfected with either control or p14ARF 
encoding expression vectors, and western blot analyses were performed after 6 days of G418 
selection. We observed that expression of p14ARF was associated with the accumulation of 
phosphorylated STAT3 at residue Y705 (pSTAT3-Y705) (Figure 2a). In contrast, no apparent 
modification of STAT5, AKT, or ERK status was found in the same conditions. To add 
further evidence that p14ARF promotes the accumulation of pSTAT3-Y705, H1975 cells were 
transiently transfected with an empty vector or with a p14ARF encoding vector, and 48 hours 
post-transfection the expression level of phosphorylated STAT3 was evaluated by pSTAT3-
Y705 staining in p14ARF-transfected cells followed by FACS analysis. Again, a higher level of 
pSTAT3-Y705 was found in p14ARF-transfected cells compared to control-transfected cells 
(Figure 2b). Conversely, a strong downregulation of pSTAT3-Y705 expression was observed 
when H1975 cells were deprived of p14ARF by siRNA treatment (Figure 2c). Similar 
accumulation of pSTAT3-Y705 by p14ARF was found when using the H3255 model 
(Supplementary Figure S2). When activated by tyrosine kinase signals, pSTAT3 accumulates 
in the nucleus to regulate gene expression (Levy and Darnell, 2002). Using 
immunofluorescence staining, we observed that transfection of p14ARF induced the nuclear 
accumulation of pSTAT3-Y705 (Figure 2d). To analyse whether accumulation of pSTAT3-
Y705 was indeed involved in p14ARF-mediated apoptosis, we neutralized the STAT3 pathway 
by treating H1975 cells transfected with either control or p14ARF expression vector with the 
specific STAT3 pharmacological inhibitor cucurbitacin I. Cucurbitacin I strongly inhibited 
STAT3 phosphorylation in these cells (Figure 2e lower panel) and more importantly 
prevented apoptosis in p14ARF transfected cells compared to non treated cells (Figure 2e upper 
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panel). Of note, a slight downregulation of STAT3 expression was found in the presence of 
cucurbitacin I in agreement with autoregulation of the STAT3 gene (Ichiba et al., 1998; 
Narimatsu et al., 2001). Furthermore, decreased p14ARF expression protein levels were 
reproducibly observed in response to cucurbitacin I, suggesting the existence of a positive 
feedback loop between p14ARF and STAT3. We concluded that activation of STAT3 is critical 
for p14ARF-mediated apoptosis in EGFR mutant L858R cells. Because these data implied that 
pSTAT3-Y705 promotes apoptosis in our L858R mutant models, H1975 and H3255 cells 
were transfected with siRNA against PTP-RT, a phosphatase that specifically 
dephosphorylates STAT3 on Tyr 705 (Zhang et al., 2007). As illustrated, silencing PTP-RT 
resulted in the accumulation of pSTAT3-Y705 (Figure 3a) and strongly promoted cell death, 
as measured by caspase 3 cleavage (Figure 3a and Figure 3b). Importantly, treating PTP-RT 
knockdown cells with cucurbitacin I significantly prevented the induction of apoptosis, 
thereby demonstrating that pSTAT3-Y705 is the main target of PTP-RT in that case (Figure 
3c). Altogether, these data support the idea that STAT3 activates an intrinsic pro-apoptotic 
signalling pathway in lung tumour cells harboring the EGFR L858R mutation and indicate 
that p14ARF activates this pathway. 
 
The pro-apoptotic p14ARF/STAT3 signalling pathway targets Bcl-2 
 Phosphorylation at tyrosine 705 is critical for activation of STAT3 signal transduction 
(Levy and Darnell, 2002). Numerous STAT3 target genes have been identified and include 
regulators of apoptosis such as Bcl-xL, Bcl-2 and Bax (Haura et al., 2005a; Haura et al., 
2005b). In our cellular models expressing mutant EGFR L858R, inhibiting STAT3 expression 
(Figure 4a) or phosphorylation (Figure 4b) using specific siRNA and cucurbitacin I 
respectively, induced the accumulation of the anti-apoptotic Bcl-2 protein. Conversely, 
stimulating pSTAT3-Y705 accumulation through neutralization of PTP-RT (Figure 4c) led to 
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a Bcl-2 downregulation. In  contrast, expression of Bax and Bcl-xL did not change. Together, 
these results indicate that the STAT3-dependent pro-apoptotic pathway involves 
downregulation of Bcl-2 expression in EGFR L858R cells. In agreement with these data, 
transfecting cells with a p14ARF expression vector induced a clear downregulation of Bcl-2 
whereas p14ARF knock-down promoted Bcl-2 accumulation (Figure 4d and Supplementary 
Figure S2). In both cases, a significant deregulation of Bcl-2 transcripts was also observed 
(data not shown). In addition, treating cells with cucurbitacin I prevented the downregulation 
of Bcl-2 induced by p14ARF (Figure 4e). Overall, these data identified Bcl-2 as an important 
target of the STAT3-dependent pro-apoptotic signalling pathway in EGFR L858R cells and 
indicated that p14ARF triggers STAT3-dependent downregulation of Bcl-2 expression. 
 
The EGFR L858R mutant downregulates p14ARF expression and counteracts the 
p14ARF/STAT3 pro-apoptotic pathway 
 We previously observed that p14ARF levels are very low in human lung tumours with 
activating mutant EGFR (Mounawar et al., 2007) as well as in the H1975 and H3255 lung 
tumour cell lines (Figure 1a). Therefore, we postulated that the EGFR L858R mutant might 
inhibit p14ARF expression to counteract its pro-apoptotic function. We first transfected H1299 
lung adenocarcinoma cells with a plasmid encoding the EGFR L858R mutant and analysed 
the expression of endogenous p14ARF, either by immunofluorescence staining 2 days post-
transfection (Figure 5a) or by western blotting after 6 days of G418 selection (Figure 5b). In 
both situations, a significant downregulation of p14ARF protein was observed in cells 
expressing the EGFR L858R mutant. Conversely, silencing EGFR L858R in both H1975 and 
H3255 cells induced the accumulation of p14ARF (Figure 5c). In order to confirm the effect of 
activated EGFR on p14ARF expression, we used the H1719 cell line that expresses wild type 
EGFR. Treating cells with EGF induced accumulation of phosphorylated EGFR (Figure 5d, 
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lower panel) and more importantly strongly downregulated p14ARF expression (Figure 5d 
upper panel). Altogether, these results demonstrate that activating EGFR either through 
mutation or after ligand binding negatively controls p14ARF expression. Finally, we 
investigated the consequences of p14ARF modulation in response to EGFR activation. 
Consistent with the hypothesis that EGFR L858R represses the pro-apoptotic 
p14ARF/STAT3/Bcl-2 signalling pathway, the downregulation of p14ARF expression following 
transfection of H1299 cells with EGFR L858R expression vector was accompanied by 
reduced levels of pSTAT3-Y705 as well as an upregulation of Bcl-2 expression (Figure 6a). 
Conversely, accumulation of pSTAT3-Y705 and downregulation of Bcl-2 were observed in 
EGFR L858R depleted cells (Figure 6b) and correlated with an induction of apoptosis (Figure 
6c) and inhibition of cell proliferation (Figure 6d). Importantly, silencing p14ARF rescued 
EGFR L858R knock-down cells from pSTAT3-Y705 accumulation and Bcl-2 downregulation 
(Figure 6b), from induction of apoptosis (Figure 6c) and from inhibition of cell proliferation 
(Figure 6d). These results demonstrate that the EGFR L858R mutant counteracts the 
p14ARF/STAT3/Bcl-2-dependent pro-apoptotic signalling pathway by a mechanism involving 
the downregulation of p14ARF. 
 
Discussion 
 Somatic activating mutations in the tyrosine kinase domain of EGFR are involved in 
the aetiology and maintenance of lung tumours through constitutive activation of AKT and 
STAT survival pathways. Recently, reduced levels of p14ARF were observed in almost all lung 
tumours harboring activating mutant EGFR, suggesting a role for the p14ARF tumour 
suppressor in the control of mutant EGFR signalling. Here, we demonstrate that p14ARF is a 
potent growth inhibitor of lung tumour cells expressing the EGFR L858R activating mutation 
and promotes cell death by activating a pro-apoptotic STAT3 pathway. In addition, we show 
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that the EGFR L858R mutant counteracts the anti-proliferative function of p14ARF by 
repressing its expression and STAT3-dependent pro-apoptotic signalling. These results 
identify a novel cross talk between the p14ARF and EGFR pathways and suggest that 
inactivation of p14ARF cooperates with activated EGFR to promote lung tumourigenesis. 
 We show that transient expression of p14ARF induces apoptosis in EGFR L858R 
mutant cells and that STAT3 is an important factor in signalling p14ARF-mediated cell death. 
STAT3 activation has been associated with proliferation, survival and cellular transformation. 
However, there are a number of examples where activated STAT3 appears to play a role in 
differentiation and in promoting apoptosis (Chapman et al., 1999; Minami et al., 1996; 
Nakajima et al., 1996; O'Farrell et al., 1998). In one such example, STAT3 activation has an 
established pro-apoptotic role during involution of the mammary gland (Chapman et al., 
1999). In this study, we show that blocking STAT3 activation prevents ARF-mediated 
apoptosis. This suggests that a pro-apoptotic STAT3 signalling pathway contributes to growth 
inhibition of EGFR L858R mutant cells by p14ARF. In addition, we demonstrate that activated 
pSTAT3-Y705 accumulates in p14ARF-transfected cells and promotes the downregulation of 
Bcl-2 expression. These results suggest that p14ARF represses the transcriptional activity of 
STAT3 towards Bcl-2. It has been reported that Tip60 controls the transcriptional activity of 
STAT3 (Xiao et al., 2003). Moreover, we previously reported that p14ARF interacts with 
Tip60 and controls its ability to regulate gene expression (Leduc et al., 2006). It is tempting to 
speculate that Tip60 plays a role in STAT3-mediated repression of Bcl-2 expression by 
p14ARF. Interestingly, depleting Tip60 using siRNA in H1975 cells resulted in the 
deregulation of pSTAT3-Y705 and Bcl-2 expression (data not shown). Further experiments 
are required to decipher the mechanisms involved in the control of STAT3 activity by Tip60 
and to address the role of p14ARF in this context. 
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 Constitutive activation of AKT and STAT survival pathways correlates with 
oncogenic activity of mutant EGFRs (Greulich et al., 2005; Sordella et al., 2004). In this 
respect, mutant EGFRs have been reported to mediate indirect activation of a proliferative IL-
6/gp130/JAK/STAT3 pathway, and high levels of activated STAT3 are observed in lung 
adenocarcinoma harboring activating mutations of EGFR (Gao et al., 2007). Conversely, 
expression of mutant EGFRs appears essential for suppression of pro-apoptotic signals in lung 
cancers harboring these mutations, as their neutralization results in rapid apoptosis (Greulich 
et al., 2005; Sordella et al., 2004). However, the mechanisms and targets involved in this 
process are largely unknown. In this study, we show that a STAT3-dependent signalling 
pathway plays a role in promoting apoptosis in EGFR L858R mutant cells and that the p14ARF 
tumour suppressor activates this pathway. We also provide evidence that the EGFR L858R 
mutant downregulates p14ARF expression and therefore inhibits this STAT3-dependent pro-
apoptotic signalling. These data indicate that p14ARF is part of a failsafe mechanism protecting 
cells against untimely or excessive mitotic signals induced by EGFR L858R signalling and 
that inactivation of the ARF/STAT3 pro-apoptotic pathway contributes to mutant EGFR 
L858R dependence. This could explain the high frequency of decreased p14ARF expression in 
tumours harboring an L858R mutation in the EGFR kinase domain (Mounawar et al., 2007). 
Interestingly, our results strongly suggest that STAT3 positively regulates p14ARF expression 
identifying a positive feed-back loop between both proteins. Further experiments are required 
to elucidate whether STAT3 plays a role in the control of p14ARF expression by the EGFR 
L858R mutant. 
 Identifying the regulatory pathways that affect the oncogenic potential of mutant 
EGFRs could contribute to the development of targeted therapies in the treatment of lung 
cancer. We demonstrate that p14ARF promotes apoptosis of cells harboring the EGFR L858R 
mutation by inducing a STAT3/Bcl-2 pro-apoptotic pathway. Interestingly these data are also 
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observed in the H1975 cell line that carries a T790M drug resistant mutation in addition to the 
exon 21 substitution mutation. Therefore, manipulation of the p14ARF/STAT3 pathway might 
provide an additional therapeutic strategy in conjunction with EGFR-TKI and BH3 mimetics 
to enhance the death of cells that depend upon mutant EGFR-L858R signalling for survival, 
but also to overcome resistance of T790M-containing tumors.  
 
Materials and methods 
Cell lines, treatments, plasmids and transfection 
Calu3, A549, H358, H1299, HCC1719, H1975, H3255, H1650 and HCC827 cell lines were 
derived from human lung adenocarcinoma. HBECK3KT cells were immortalized human 
bronchial epithelial cells. Calu3, A549, H1299, H358 and HCC1719 cells carry a wild type 
EGFR, H1975 and H3255 cells harbor a missense substitution L858R in exon 21, and H1650 
and HCC827 have an E746_A750 deletion in exon 19. H1975 cells also carry a T790M 
mutation. All cell lines were cultured in 5% CO2 at 37°C in RPMI-1640 medium (GIBCO, 
Cergy Pontoise, France). Transient transfections were carried out using JetPEI (Ozyme, Saint 
Quentin Yvelines, France) according to the manufacturer’s instructions. In the growth 
suppression assay and associated western blot analyses, G418 (Geneticin, PAA, Austria) was 
added to the media 48h post-transfection and cells were maintained for 6 days to select 
vector-transfected clones. Trypan blue excluding cells were counted and total protein extracts 
were performed for western blot analyses. Plasmids used in transient transfections were 
pcDNA3.1 (used as a control), pcDNA3.1-p14ARF and pcDNA3.1-EGFR-L858R. Treatment 
with 2 μM cucurbitacin I (sc-203010, Santa Cruz, TEBU, Le Perray en Yvelines, France) was 
carried out for 24 hours. For EGF treatment, cells were incubated in serum-free medium for 
24 hours. After medium change, EGF (50ng/ml) was added for 24 hours. 
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Transfection of siRNA oligonucleotides 
The sequences designed to specifically target human p14ARF, PTP-RT and EGFR RNAs were 
as follows: p14ARF, 5’-GAACAUGGUGCGCAGGUUCTT-3’ ; PTP-RT, 5’-
GGAGGAGCCACUUCAGAAGUCACGG-3’; EGFR, 5’-CUCUGGAGGAAAAGAAAA 
GAAAGU-3’. STAT3 siRNAs were purchased from InVitrogen (Cergy Pontoise, France). 
For all interference experiments, the mismatch siRNA oligonucleotide used as a control was 
5’-UCGGCUCUUACGCAUUCAA-3’. Cells were transfected with siRNA oligonucleotide 
duplexes using Oligofectamine reagent according to the manufacturer’s instructions 
(Invitrogen, Cergy Pontoise, France). The cells were analysed 72 hours post-transfection. 
 
Western blot experiments and antibodies 
Immunoblotting was performed using whole cell extracts prepared in RIPA buffer, as 
described previously (Eymin et al., 2003). The anti-EGFR, anti-HER2/ErbB2 (M45), anti-
STAT3 (79D7), anti-pSTAT3-Y705 (D3A7), anti-STAT5 (3H7), anti-pSTAT5-Y694, anti-
AKT (C67E7), anti-pAKT-S473, anti-ERK1/2, anti-pERK1/2-Y202/204 (E10) and anti-
cleaved caspase3 (Asp175) antibodies were purchased from Cell Signalling (Ozyme, Saint 
Quentin Yvelines, France). The anti-Bcl-2 (C-2), anti-Bcl-xL (H62), anti-Bax (N20) and anti-
tubulin (B5-1-2) antibodies were purchased from Santa Cruz (TEBU, Le Perray en Yvelines, 
France). The anti-p14ARF (Ab1) antibody was from Calbiochem (VWR, Fontenay-sous-Bois, 
France), and the anti-Actin antibody was purchased from Sigma (Saint Quentin Fallavier, 
France)). 
 
Indirect immunofluorescence 
For immunolocalisation studies, cells were fixed with 2% paraformaldehyde in PBS for 10 
min at room temperature, washed once with PBS, and permeabilised with 0.1% Triton X-100 
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in PBS for 10 min. Blocking was performed for 45 min in 5% BSA and incubation with anti-
p14ARF (Ab2) antibody from Calbiochem (VWR, Fontenay-sous-Bois, France) or anti-
STAT3-Y705 (D3A7) antibody from Cell Signalling (Ozyme, Saint Quentin Yvelines, 
France) was carried out overnight at 4°C in a humid chamber. Cells were then incubated for 
45 min with Alexa 488 or Alexa 568, mounted in a solution containing 4,6-diamino-2-
phenylindole (DAPI) (Vectashield, Clinisciences, Montrouge, France) and visualised using an 
Olympus BX41 microscope. For evaluation of phosphorylated STAT3 expression, cells were 
fixed with 0.5% paraformaldehyde in PBS for 5 min on ice, washed three times with PBS, 
and permeabilised with 0.1% Triton X-100 in PBS for 5 min at room temperature. Blocking 
was performed for 30 min in 5% BSA at room temperature and incubation with anti-p14ARF 
(Ab2) antibody from Calbiochem (VWR, Fontenay-sous-Bois, France) and anti-STAT3-Y705 
(D3A7) antibody from Cell Signalling (Ozyme, Saint Quentin Yvelines, France) was carried 
out in 1% BSA in PBS for 1 hour. Cells were then incubated for 30 min with Alexa 488 or 
Alexa 568. After being washed with PBS, cells were resuspended in PBS and subjected to 
flow cytometric analysis using a FACScan flow cytometer (BD Biosciences, Le Pont de 
Claix, France). pSTAT3-Y705 staining was assessed on p14ARF stained cells.  
 
Quantitative RT-PCR analysis 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Courtaboeuf, France) and 
subjected to quantitative RT-PCR, as described previously (Van Den Broeck et al., 2008). 
The primers used for mRNA amplification were as follows : PTP-RT forward: 5’-
GGTTGCTAATCTGGGCAAGT-3’; PTP-RT reverse: 5’-CTGAGCTCTGTCCACCACAA-
3’; GAPDH forward: 5’-CGAGATCCCTCCAAAATCAA-3’; GAPDH reverse: 5’-
ATCCACAGTCTTCTGGGTGG-3’. Amplification of GAPDH was performed in all 
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experiments and used as a reference gene. Relative gene expression was calculated for each 
sample as the ratio of target gene mRNA copy number to GAPDH mRNA copy number. 
 
Apoptosis analysis  
Induced apoptosis following neutralization of EGFR was studied on a total cell population 
using the PE-conjugated monoclonal active caspase 3 antibody apoptosis kit (BD Biosciences, 
Pharmingen, Le Pont de Claix, France) according to the manufacturer’s protocol. For the 
study of apoptosis following ARF transfection, a modified protocol was applied, allowing 
analysis of cells co-stained with ARF and active caspase 3 antibodies. In brief, cells were 
fixed with 0.5% paraformaldehyde for 5 min at 4°C and subsequently permeabilised with 
0.1% Triton X-100 in PBS for 5 min. Cells were blocked with 5% BSA for 30 min at room 
temperature. Cells were then incubated for 1 hour with anti-p14ARF antibody (Ab2, 
Calbiochem) in 1% BSA in PBS, washed 2 times with PBS and incubated for an additional 1 
hour with Alexa 488 and PE-conjugated active caspase 3 antibody (BD Biosciences, 
Pharmingen, Le Pont de Claix, France). After being washed with PBS, cells were resuspended 
in PBS and subjected to flow cytometric analysis using a FACScan flow cytometer (BD 
Biosciences, Le Pont de Claix, France). Active caspase 3 staining was assessed on ARF 
stained cells. 
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Titles and legends to figures 
Figure 1: p14ARF inhibits the growth of EGFR L858R mutant cells by inducing apoptosis.  
(a), Western blot analysis of p14ARF expression in cell lines with different EGFR/HER2 
status. Tubulin was used as a loading control. (b), H1975 cells were transfected with either 
control (Ctl) or p14ARF encoding vector and subjected to G418 selection for 6 days. Cell 
number was evaluated after trypan blue staining. Expression of transfected p14ARF was 
studied by western blot analysis. Actin was used as a loading control. (c), H1975 cells were 
transfected with control (Ctl) or p14ARF expressing vector for 72 h. Apoptosis was evaluated 
by active caspase 3 staining in p14ARF-transfected cells followed by FACS analysis. (d), 
H1975 cells were transfected with either control (Ctl) or p14ARF siRNA for 72 hours. Cell 
number was evaluated after trypan blue staining. Efficiency of p14ARF depletion was assessed 
by western blot analysis.  
 
Figure 2: p14ARF-mediated apoptosis involves the accumulation of pSTAT3-Y705.  
(a), H1975 cells were transfected with control (Ctl) empty or p14ARF encoding vector and 
subjected to western blot analysis with indicated antibodies following a 6 days G418 
selection. Actin was used as a loading control. (b), H1975 cells were transfected with control 
(Ctl) empty or p14ARF encoding vector for 48 hours. The expression level of pSTAT3 was 
evaluated by pSTAT3 staining in p14ARF-transfected cells followed by FACS analysis. (c), 
H1975 cells were transfected with control or p14ARF siRNA. Western blotting was performed 
using indicated antibodies. Actin was used as a loading control. (d), H1975 cells were 
transfected with either control (Ctl) empty or p14ARF expressing vector for 48 hours. Co-
localisation of p14ARF (green) and pSTAT3-Y705 (red) was visualised by 
immunofluorescence. DAPI (blue) was used to counterstain nuclei. (e), H1975 cells were 
transfected with either control (Ctl) empty or p14ARF expressing vector for 48 hours and 
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treated for 24 additional hours with cucurbitacin I (2 μM). Apoptosis was evaluated by active 
caspase 3 staining in p14ARF-transfected cells followed by FACS analysis. Apoptosis was 
expressed as the ratio between control and p14ARF transfected cells in each condition (with or 
without cucurbitacin I). The number of apoptotic cells in control-transfected cells (Ctl) was 
normalized to 1. Data represent the mean ± S.D. of three independent experiments. Inhibition 
of STAT3 phosphorylation by cucurbitacin I and expression of p14ARF were assessed by 
western blotting. Tubulin was used as a loading control. 
 
Figure 3: Existence of intrinsic STAT3-dependent pro-apoptotic signalling in EGFR L858R 
cells.  
H1975 and H3255 cells were transfected for 72 hours with either control (Ctl) or PTP-RT 
siRNA. (a) Total cellular extracts were subjected to western blot analysis with indicated 
antibodies. Tubulin was used as a loading control. Neutralization of PTP-RT was assessed by 
RT-QPCR. GAPDH was used as an internal control. (b) Apoptosis was evaluated by active 
caspase 3 staining, followed by FACS analysis. Relative levels of apoptotic cells were 
calculated as described below. (c) H1975 cells were transfected with either control (Ctl) or 
siRNA against PTP-RT for 48 hours and incubated with Cucurbitacin I (2μM) for 24 
additional hours. Total cellular extracts were subjected to western blot analysis with indicated 
antibodies. Tubulin was used as a loading control. Apoptosis was evaluated by active caspase 
3 staining, followed by FACS analysis. Relative levels of apoptotic cells were calculated as 
described below. 
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Figure 4: Bcl-2 is a critical target of p14ARF/STAT3-dependent pro-apoptotic signalling 
pathway.  
(a) H1975 and H3255 cells were transfected for 72 hours with either control (Ctl) or STAT3 
siRNA. Total cellular extracts were subjected to western blot analysis with the indicated 
antibodies. Tubulin was used as a loading control. (b) H1975 and H3255 cells were incubated 
for 24 hours with cucurbitacin I (2 μM). Bcl-2, STAT3 and pSTAT3-Y705 were detected by 
western blot analysis. Tubulin was used as a loading control. (c) H1975 and H3255 cells were 
transfected for 72 hours with control (Ctl) or siRNA against PTP-RT. Total cellular extracts 
were subjected to western blot analysis with indicated antibodies. Depletion of PTP-RT was 
assessed by RT-QPCR. GAPDH was used as an internal control. (d) H1975 cells were 
transfected with either p14ARF encoding vectors or p14ARF siRNA and subjected to western 
blot analysis with indicated antibodies. Actin was used as a loading control. (e) H1975 cells 
were transfected for 48 h with control (-) or p14ARF (+) expressing vector and treated for an 
additional 24 hours with cucurbitacin (2 μM). Western blotting was performed on total 
cellular extracts. Tubulin was used as a loading control.  
 
Figure 5: The EGFR L858R mutant downregulates p14ARF expression.  
(a) H1299 cells were transfected for 24 hours with either control (Ctl) empty or EGFR L858R 
expression vector. Expression of p14ARF (green) and EGFR L858R (red) was analysed by 
immunofluorescence using anti-p14ARF and anti-phospho EGFR antibodies, respectively. 
DAPI (blue) was used to counterstain nuclei. (b) H1299 cells were transfected with either 
control (Ctl) empty vector or EGFR L858R expression vector and selected for 6 days with 
G418. Total cellular extracts were subjected to western blot analysis with indicated 
antibodies. Actin was used as a loading control. The relative densitometric areas for p14ARF 
were determined according to actin signal and arbitrarily assigned to 1 in control cells. (c) 
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H1975 and H3255 cells were transfected with either control (Ctl) or EGFR siRNA for 72 
hours. Total cellular extracts were subjected to western blot analysis with indicated 
antibodies. Tubulin was used as a loading control. A relative p14ARF/tubulin ratio was 
calculated as described below. (d) Total cellular extracts were prepared from unstimulated or 
EGF-stimulated H1719 cells for 24 hours and subjected to western blot analysis with 
indicated antibodies. A 30 min EGF stimulation was performed to confirm EGFR activation. 
Tubulin was used as a loading control. A relative p14ARF/tubulin ratio was calculated as 
described below. 
 
Figure 6: Mutant EGFR L858R counteracts the pro-apoptotic p14ARF/STAT3/Bcl-2 pathway.  
(a) H1299 cells were transfected with either empty (Ctl) or EGFR L858R expression vector 
and selected for 6 days with G418. Expression of EGFR, STAT3, pSTAT3-Y705 and Bcl-2 
proteins was studied by western blot analysis. Tubulin was used as a loading control. (b-d) 
H1975 and H3255 cells were transfected for 72 hours with either control (Ctl) or siRNAs 
against EGFR and/or p14ARF. (b) Total cellular extracts were subjected to western blot 
analysis using indicated antibodies. Tubulin was used as a loading control. (c) Apoptosis was 
studied by active caspase3 staining, followed by FACS analysis. Apoptosis was expressed as 
the ratio between control and sip14ARF/siEGFR transfected cells. The number of apoptotic 
cells in control-transfected cells (Ctl) was normalised to 1. Data represent the mean ± S.D. of 
three independent experiments. (d) Cell number was evaluated after trypan blue staining.  
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